Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Emmy Awards Producers Approach Chris Rock And Dwayne Johnson For Hosting Duties: Report

An effort is underway to attract Chris Rock and/or Dwayne Johnson as potential hosts of the 74th Primetime Emmy Awards, which will be broadcast on Sept. 12 on NBC, a division of Comcast Corporation (NASDAQ: CMCSA).

Benzinga

Ominous Death Cross Forms On Keurig Dr Pepper's Chart

If history is any guide, there may be trouble ahead for shares of Keurig Dr Pepper (NASDAQ:KDP). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Ominous Death Cross Forms On Costco Wholesale's Chart

If history is any guide, there may be trouble ahead for shares of Costco Wholesale (NASDAQ:COST). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Here's Why Needham Sees Apple's Brand Value Worth At $1T

Needham analyst Laura Martin believes lifetime value (LTV) is the primary driver of upside value for Apple Inc (NASDAQ: AAPL) and that brand value is a leading indicator of LTV in a note titled "AAPL's Brand is Worth $1 Trillion."

Benzinga

Looking At Advanced Micro Devices's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Advanced Micro Devices (NASDAQ:AMD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In Tesla 10 Years Ago Would Be Worth Today

Tesla (NASDAQ:TSLA) has outperformed the market over the past 10 years by 48.14% on an annualized basis producing an average annual return of 58.9%. Currently, Tesla has a market capitalization of $683.52 billion.

Benzinga

$1000 Invested In T-Mobile US 5 Years Ago Would Be Worth This Much Today

T-Mobile US (NASDAQ:TMUS) has outperformed the market over the past 5 years by 6.27% on an annualized basis producing an average annual return of 14.94%. Currently, T-Mobile US has a market capitalization of $160.94 billion.

Benzinga

How Is The Market Feeling About Lululemon Athletica?

Lululemon Athletica's (NASDAQ:LULU) short percent of float has fallen 5.64% since its last report. The company recently reported that it has 2.79 million shares sold short, which is 2.51% of all regular shares that are available for trading.

Benzinga

HTG Molecular Diagnostics's Return On Capital Employed Insights

HTG Molecular Diagnostics (NASDAQ:HTGM) brought in sales totaling $1.18 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 25.16%, resulting in a loss of $6.50 million.

Benzinga

NeuroPace Earnings Perspective: Return On Capital Employed

Benzinga Pro data, NeuroPace (NASDAQ:NPCE) reported Q1 sales of $11.37 million. Earnings fell to a loss of $11.46 million, resulting in a 7.18% decrease from last quarter.

Benzinga

Acutus Medical's Return On Capital Employed Overview

Benzinga Pro data, Acutus Medical (NASDAQ:AFIB) reported Q1 sales of $3.68 million. Earnings fell to a loss of $40.02 million, resulting in a 28.0% decrease from last quarter.

Benzinga

CASI Pharmaceuticals's Return On Capital Employed Insights

Benzinga Pro data, CASI Pharmaceuticals (NASDAQ:CASI) reported Q1 sales of $9.06 million. Earnings fell to a loss of $8.40 million, resulting in a 55.7% decrease from last quarter.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Aptevo Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Aptevo Therapeutics (NASDAQ:APVO) reported Q1 sales of $3.11 million. Earnings fell to a loss of $7.70 million, resulting in a 22.72% decrease from last quarter.

Benzinga

Cyxtera Technologies Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q1, Cyxtera Technologies (NASDAQ:CYXT) posted sales of $182.40 million. Earnings were up 37.65%, but Cyxtera Technologies still reported an overall loss of $40.90 million.

Benzinga

Dynatronics's Return On Capital Employed Insights

Dynatronics (NASDAQ:DYNT) brought in sales totaling $10.32 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 2.1%, resulting in a loss of $1.47 million.

Benzinga

4 Analysts Have This to Say About Intapp

Intapp (NASDAQ:INTA) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benchmark Bullish On Hub Group, Sees 30% Upside

Benchmark analyst Christopher Kuhn initiated coverage of Hub Group Inc (NASDAQ:HUBG) with a Buy rating and a price target of $90, implying an upside of 31%. According to the analyst, intermodal volume growth will turn positive in 2022. Kuhn anticipates growth to continue in 2022, but he sees margins normalizing in 2023 as pricing…

Benzinga

4 Analysts Have This to Say About Centessa Pharmaceuticals

Analysts have provided the following ratings for Centessa Pharmaceuticals (NASDAQ:CNTA) within the last quarter:

Benzinga

Where Urban Outfitters Stands With Analysts

Within the last quarter, Urban Outfitters (NASDAQ:URBN) has observed the following analyst ratings:

Benzinga

What To Watch For On Advanced Micro Devices Stock As It Continues In This Trend

Advanced Micro Devices, Inc. (NASDAQ: AMD) plunged more than 8% on Thursday and was trading slightly higher when the markets opened on Friday.

Benzinga

VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate

VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).

Benzinga

Final Draft Of Macau Gaming Law: What Investors Need To Know

The Macau Legislative Assembly signed the final draft of the new Macau gaming law this week. Bank of America analyst Billy Ng says there's nothing in the legislation that dampens his long-term bullish thesis on the Macau gaming market. Draft Updates: The final draft of the law includes the following…

Benzinga

Why Shares Of Addex Therapeutics Are Falling Today

Shares of small-cap penny stock Addex Therapeutics Ltd. (NASDAQ: ADXN) are trading lower after the company terminated its Phase 2b/3 study of Dipraglurant for dyskinesia associated with Parkinson's disease due to slow recruitment. The company suspended its guidance amid the termination.

1 … 424 425 426 427

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.